X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Sun Pharma with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs MYLAN (US) - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SUN PHARMA   MYLAN
EQUITY SHARE DATA
    SUN PHARMA
Mar-17
MYLAN
Dec-14
SUN PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs8424,159-   
Low Rs5722,931-   
Sales per share (Unadj.) Rs131.61,423.7-  
Earnings per share (Unadj.) Rs32.7171.5-  
Cash flow per share (Unadj.) Rs38.0276.1-  
Dividends per share (Unadj.) Rs3.500-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs152.7707.7-  
Shares outstanding (eoy) m2,399.26378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x5.42.5 215.8%   
Avg P/E ratio x21.620.7 104.6%  
P/CF ratio (eoy) x18.612.8 145.1%  
Price / Book Value ratio x4.65.0 92.5%  
Dividend payout %10.70-   
Avg Mkt Cap Rs m1,696,8771,341,255 126.5%   
No. of employees `00017.525.0 70.1%   
Total wages/salary Rs m49,0230-   
Avg. sales/employee Rs Th18,028.321,548.1 83.7%   
Avg. wages/employee Rs Th2,798.80-   
Avg. net profit/employee Rs Th4,479.52,595.8 172.6%   
INCOME DATA
Net Sales Rs m315,784538,702 58.6%  
Other income Rs m6,232-3,140 -198.4%   
Total revenues Rs m322,016535,562 60.1%   
Gross profit Rs m100,893133,978 75.3%  
Depreciation Rs m12,64839,565 32.0%   
Interest Rs m3,99823,237 17.2%   
Profit before tax Rs m90,47968,036 133.0%   
Minority Interest Rs m0-279 0.0%   
Prior Period Items Rs m990-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m12,1162,861 423.5%   
Profit after tax Rs m78,46264,895 120.9%  
Gross profit margin %31.924.9 128.5%  
Effective tax rate %13.44.2 318.4%   
Net profit margin %24.812.0 206.3%  
BALANCE SHEET DATA
Current assets Rs m329,537473,590 69.6%   
Current liabilities Rs m178,870370,253 48.3%   
Net working cap to sales %47.719.2 248.7%  
Current ratio x1.81.3 144.0%  
Inventory Days Days7978 101.2%  
Debtors Days Days83107 77.6%  
Net fixed assets Rs m204,766124,627 164.3%   
Share capital Rs m2,39919,050 12.6%   
"Free" reserves Rs m363,9970-   
Net worth Rs m366,397267,788 136.8%   
Long term debt Rs m14,361400,049 3.6%   
Total assets Rs m614,1021,078,624 56.9%  
Interest coverage x23.63.9 601.6%   
Debt to equity ratio x01.5 2.6%  
Sales to assets ratio x0.50.5 103.0%   
Return on assets %13.48.2 164.3%  
Return on equity %21.424.2 88.4%  
Return on capital %24.813.6 182.3%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m19,6340-   
CASH FLOW
From Operations Rs m70,82270,813 100.0%  
From Investments Rs m-42,216-55,845 75.6%  
From Financial Activity Rs m-22,854-18,659 122.5%  
Net Cashflow Rs m6,107-3,691 -165.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 69.78 Rs / USD

Compare SUN PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare SUN PHARMA With: ALEMBIC LTD  TTK HEALTHCARE  PFIZER  WYETH LTD  CADILA HEALTHCARE  



Today's Market

Sensex Trims Losses; Rupee Devalues to Record Low(12:30 pm)

Stock markets in India trim losses to turn flat even as rupee fell 43 paise to hit record low of 70.29 against the US dollar.

Related Views On News

SUN PHARMA at 52 Week High; BSE 500 Index Down 0.1 % (Market Updates)

Aug 16, 2018 | Updated on Aug 16, 2018

SUN PHARMA share price has hit a 52-week high. It is presently trading at Rs 610. BSE 500 Index is down by 0.1% at 15,415. Within the BSE 500, SUN PHARMA (up 1.4%) and AIA ENGINEERING (up 5.4%) are among the top gainers, while top losers are NARAYANA HRUDAYALAYA LTD and TECHNO ELECTRIC.

SUN PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 12.0% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, SUN PHARMA has posted a net profit of Rs 16 bn (up 12.0% YoY). Sales on the other hand came in at Rs 70 bn (down 2.2% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Aug 16, 2018 01:39 PM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS